ID   SCC-9
AC   CVCL_1685
SY   SCC 9; SCC9
DR   BTO; BTO:0005855
DR   CLO; CLO_0008969
DR   EFO; EFO_0006485
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1629
DR   BCRJ; 0196
DR   BioGRID_ORCS_Cell_line; 1006
DR   BioSample; SAMN03473154
DR   BioSample; SAMN10987925
DR   cancercelllines; CVCL_1685
DR   Cell_Model_Passport; SIDM01080
DR   ChEMBL-Cells; CHEMBL3308782
DR   ChEMBL-Targets; CHEMBL1075571
DR   Cosmic; 909709
DR   Cosmic; 921834
DR   Cosmic; 1175847
DR   Cosmic; 1339929
DR   Cosmic; 1530757
DR   Cosmic; 2266781
DR   Cosmic; 2296303
DR   Cosmic; 2513911
DR   Cosmic; 2546841
DR   Cosmic-CLP; 909709
DR   DepMap; ACH-000181
DR   ECACC; 89062003
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 909709
DR   GEO; GSM422870
DR   GEO; GSM423673
DR   GEO; GSM887561
DR   GEO; GSM888644
DR   GEO; GSM1374866
DR   GEO; GSM1670412
DR   GEO; GSM7695974
DR   GEO; GSM7695975
DR   IARC_TP53; 1688
DR   IGRhCellID; SCC9%20GSE9585
DR   LiGeA; CCLE_732
DR   LINCS_LDP; LCL-1225
DR   PharmacoDB; SCC9_1356_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1685
DR   PubChem_Cell_line; CVCL_1685
DR   RCB; RCB0718
DR   TOKU-E; 3099
DR   Wikidata; Q54952359
RX   DOI=10.1007/978-1-4615-2023-8_7;
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RX   PubMed=1423286;
RX   PubMed=1574572;
RX   PubMed=2394610;
RX   PubMed=2573646;
RX   PubMed=3458227;
RX   PubMed=7214336;
RX   PubMed=8390283;
RX   PubMed=17312569;
RX   PubMed=17325662;
RX   PubMed=20014447;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21868764;
RX   PubMed=22460905;
RX   PubMed=25275298;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=29156801;
RX   PubMed=30135316;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=32990596;
RX   PubMed=35839778;
RX   PubMed=37949965;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: OPC-22 oral and pharyngeal cancer cell line panel.
CC   Population: Caucasian.
CC   HLA typing: A*01:01,02:01; B*35:03,44:03; C*04:01,16:02; DQA1*01:02,05:02; DRB1*01:16,13:14 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274_Glu285del (c.820_851del32); Zygosity=Unspecified (PubMed=1423286; PubMed=25275298).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.25%; Native American=0.1%; East Asian, North=1.78%; East Asian, South=0.03%; South Asian=6.17%; European, North=30.07%; European, South=61.6% (PubMed=30894373).
CC   Discontinued: RCB; RCB0718; true.
CC   Derived from site: In situ; Oral cavity, tongue, anterior part; UBERON=UBERON_0010032.
ST   Source(s): ATCC; Cosmic-CLP; PubMed=21868764; PubMed=25275298; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 9
ST   D16S539: 10,11
ST   D18S51: 12,14
ST   D21S11: 28
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 8
ST   D8S1179: 13
ST   FGA: 20,25
ST   Penta D: 9
ST   Penta E: 11
ST   TH01: 8,9
ST   TPOX: 9,11
ST   vWA: 17
DI   NCIt; C4648; Tongue squamous cell carcinoma
DI   ORDO; Orphanet_457252; Squamous cell carcinoma of the oral tongue
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   25Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 41
//
RX   DOI=10.1007/978-1-4615-2023-8_7;
RA   Weichselbaum R.R., Beckett M.A., Vokes E.E., Brachman D.G.,
RA   Haraf D., Hallahan D.E., Kufe D.W.;
RT   "Cellular and molecular mechanisms of radioresistance.";
RL   (In) Head and neck cancer. Cancer treatment and research, Vol. 74; Hong W.K., Weber R.S. (eds.); pp.131-140; Springer; Boston (1995).
//
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RA   Carey T.E.;
RT   "Head and neck tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York (1994).
//
RX   PubMed=1423286;
RA   Jung M., Notario V., Dritschilo A.;
RT   "Mutations in the p53 gene in radiation-sensitive and -resistant human
RT   squamous carcinoma cells.";
RL   Cancer Res. 52:6390-6393(1992).
//
RX   PubMed=1574572; DOI=10.2307/3578273;
RA   Dunphy E.J., Beckett M.A., Thompson L.H., Weichselbaum R.R.;
RT   "Expression of the polymorphic human DNA repair gene XRCC1 does not
RT   correlate with radiosensitivity in the cells of human head and neck
RT   tumor cell lines.";
RL   Radiat. Res. 130:166-170(1992).
//
RX   PubMed=2394610; DOI=10.1016/0360-3016(90)90539-V;
RA   Weichselbaum R.R., Beckett M.A., Vijayakumar S., Simon M.A.,
RA   Awan A.M., Nachman J., Panje W.R., Goldman M.E., Tybor A.G.,
RA   Moran W.J., Vokes E.E., Ahmed-Swan S., Farhangi E.;
RT   "Radiobiological characterization of head and neck and sarcoma cells
RT   derived from patients prior to radiotherapy.";
RL   Int. J. Radiat. Oncol. Biol. Phys. 19:313-319(1990).
//
RX   PubMed=2573646; DOI=10.1080/09553008914551731;
RA   Weichselbaum R.R., Rotmensch J., Ahmed-Swan S., Beckett M.A.;
RT   "Radiobiological characterization of 53 human tumor cell lines.";
RL   Int. J. Radiat. Biol. 56:553-560(1989).
//
RX   PubMed=3458227; DOI=10.1073/pnas.83.8.2684;
RA   Weichselbaum R.R., Dahlberg W.K., Beckett M.A., Karrison T., Miller D.,
RA   Clark J., Ervin T.J.;
RT   "Radiation-resistant and repair-proficient human tumor cells may be
RT   associated with radiotherapy failure in head- and neck-cancer
RT   patients.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:2684-2688(1986).
//
RX   PubMed=7214336;
RA   Rheinwald J.G., Beckett M.A.;
RT   "Tumorigenic keratinocyte lines requiring anchorage and fibroblast
RT   support cultured from human squamous cell carcinomas.";
RL   Cancer Res. 41:1657-1663(1981).
//
RX   PubMed=8390283; DOI=10.1038/bjc.1993.238;
RA   Burns J.E., Baird M.C., Clark L.J., Burns P.A., Edington K.G.,
RA   Chapman C., Mitchell R., Robertson G., Soutar D., Parkinson E.K.;
RT   "Gene mutations and increased levels of p53 protein in human squamous
RT   cell carcinomas and their cell lines.";
RL   Br. J. Cancer 67:1274-1284(1993).
//
RX   PubMed=17312569; DOI=10.1002/hed.20478;
RA   Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L.,
RA   Koch W.M., Ferris R.L., Lai S.Y.;
RT   "Head and neck squamous cell carcinoma cell lines: established models
RT   and rationale for selection.";
RL   Head Neck 29:163-188(2007).
//
RX   PubMed=17325662; DOI=10.1038/sj.onc.1210330;
RA   Nakaya K., Yamagata H.D., Arita N., Nakashiro K.-i., Nose M., Miki T.,
RA   Hamakawa H.;
RT   "Identification of homozygous deletions of tumor suppressor gene FAT
RT   in oral cancer using CGH-array.";
RL   Oncogene 26:5300-5308(2007).
//
RX   PubMed=20014447; DOI=10.1002/hed.21311;
RA   Tsui I.F.L., Garnis C.;
RT   "Integrative molecular characterization of head and neck cancer cell
RT   model genomes.";
RL   Head Neck 32:1143-1160(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25275298; DOI=10.18632/oncotarget.2417;
RA   Martin D., Abba M.C., Molinolo A.A., Vitale-Cross L., Wang Z.-Y.,
RA   Zaida M., Delic N.C., Samuels Y., Lyons J.G., Gutkind J.S.;
RT   "The head and neck cancer cell oncogenome: a platform for the
RT   development of precision molecular therapies.";
RL   Oncotarget 5:8906-8923(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29156801; DOI=10.18632/oncotarget.21174;
RA   Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y.,
RA   Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J.,
RA   Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.;
RT   "Genomic characterization of human papillomavirus-positive and
RT   -negative human squamous cell cancer cell lines.";
RL   Oncotarget 8:86369-86383(2017).
//
RX   PubMed=30135316; DOI=10.1172/jci.insight.122204;
RA   Jamieson S.M.F., Tsai P., Kondratyev M.K., Budhani P., Liu A.,
RA   Senzer N.N., Chiorean E.G., Jalal S.I., Nemunaitis J.J., Kee D.,
RA   Shome A., Wong W.W., Li D., Poonawala-Lohani N., Kakadia P.M.,
RA   Knowlton N.S., Lynch C.R.H., Hong C.R., Lee T.W., Grenman R.,
RA   Caporiccio L., McKee T.D., Zaidi M., Butt S., Macann A.M.J.,
RA   McIvor N.P., Chaplin J.M., Hicks K.O., Bohlander S.K., Wouters B.G.,
RA   Hart C.P., Print C.G., Wilson W.R., Curran M.A., Hunter F.W.;
RT   "Evofosfamide for the treatment of human papillomavirus-negative head
RT   and neck squamous cell carcinoma.";
RL   JCI Insight 3:e122204.1-e122204.19(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=32990596; DOI=10.7554/eLife.57761;
RA   Chai A.W.Y., Yee P.S., Price S., Yee S.M., Lee H.M., Tiong V.K.H.,
RA   Goncalves E., Behan F.M., Bateson J., Gilbert J.G.R., Tan A.-C.,
RA   McDermott U., Garnett M.J., Cheong S.-C.;
RT   "Genome-wide CRISPR screens of oral squamous cell carcinoma reveal
RT   fitness genes in the Hippo pathway.";
RL   eLife 9:e57761.1-e57761.34(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//
RX   PubMed=37949965; DOI=10.1038/s41598-023-46926-y;
RA   Komune N., Sato K., Ono M., Imaizumi A., Masuda S., Itoyama S.,
RA   Manako T., Kuga R., Hongo T., Kogo R., Onishi H., Nakagawa T.;
RT   "Biological and genetic characterization of a newly established human
RT   external auditory canal carcinoma cell line, SCEACono2.";
RL   Sci. Rep. 13:19636-19636(2023).
//